To dry or not too dry: should we be more tolerant of stable subretinal fluid in patients receiving anti‐vascular endothelial growth factor treatment for neovascular age‐related macular degeneration?

Publisher： John Wiley & Sons Inc

E-ISSN： 1442-9071|43|8|707-710

ISSN： 1442-6404

Source： CLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Vol.43, Iss.8, 2015-11, pp. : 707-710

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti vascular endothelial growth factor sequential therapy for neovascular age-related macular degeneration: is this the new deal?

By Neri Piergiorgio   Mariotti Cesare   Arapi Ilir   Bambini Elisa   Giovannini Alfonso  

Current Medical Research and Opinion, Vol. 28, Iss. 3, 2012-03 ,pp. : 395-400

Informa Healthcare

Access to resources Recommend Favorite

Anti‐vascular endothelial growth factors treatment of wet age‐related macular degeneration: from neurophysiology to cost‐effectiveness

By  

ACTA OPHTHALMOLOGICA, Vol. 96, Iss. A109, 2018-02 ,pp. : 1-46

John Wiley & Sons Inc

Access to resources Recommend Favorite

Spontaneous anatomical improvement on OCT findings in patients with neovascular age‐related macular degeneration without anti‐VEGF treatment

By  

ACTA OPHTHALMOLOGICA, Vol. 94, Iss. S256, 2016-10 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Aqueous vascular endothelial growth factor and aflibercept concentrations after bimonthly intravitreal injections of aflibercept for age‐related macular degeneration

By  

CLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Vol. 46, Iss. 1, 2018-01 ,pp. : 46-53

John Wiley & Sons Inc

Access to resources Recommend Favorite

Photobiomodulation in dry age‐related macular degeneration

By  

ACTA OPHTHALMOLOGICA, Vol. 96, Iss. 1, 2018-02 ,pp. : e92-e92

John Wiley & Sons Inc

Access to resources Recommend Favorite